These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23697980)

  • 1. The mTOR signaling pathway in pediatric neuroblastoma.
    Mei H; Wang Y; Lin Z; Tong Q
    Pediatr Hematol Oncol; 2013 Oct; 30(7):605-15. PubMed ID: 23697980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours.
    Iżycka-Świeszewska E; Drożyńska E; Rzepko R; Kobierska-Gulida G; Grajkowska W; Perek D; Balcerska A
    Pol J Pathol; 2010; 61(4):192-8. PubMed ID: 21290341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin inhibits proliferation and induces autophagy in human neuroblastoma cells.
    Lin X; Han L; Weng J; Wang K; Chen T
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30393233
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting β3-adrenergic receptor signaling inhibits neuroblastoma cell growth via suppressing the mTOR pathway.
    Deng J; Jiang P; Yang T; Huang M; Qi W; Zhou T; Yang Z; Zou Y; Gao G; Yang X
    Biochem Biophys Res Commun; 2019 Jun; 514(1):295-300. PubMed ID: 31030945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isatin inhibits the invasion of human neuroblastoma SH‑SY5Y cells, based on microarray analysis.
    Zhang L; Sun W; Cao Y; Hou L; Ju C; Wang X
    Mol Med Rep; 2019 Aug; 20(2):1700-1706. PubMed ID: 31257543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mTOR protein as a target in thyroid cancer.
    Souza EC; Ferreira AC; Carvalho DP
    Expert Opin Ther Targets; 2011 Sep; 15(9):1099-112. PubMed ID: 21702716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy.
    Yang S; Zheng J; Ma Y; Zhu H; Xu T; Dong K; Xiao X
    Oncol Rep; 2012 Jul; 28(1):186-92. PubMed ID: 22576801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
    Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
    Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity.
    Yang H; Wang X; Zhang Y; Liu H; Liao J; Shao K; Chu Y; Liu G
    J Cell Physiol; 2014 Jan; 229(1):17-26. PubMed ID: 23804073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
    Défachelles AS; Cougnenc O; Carpentier P
    Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
    Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
    Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
    Diaz-Padilla I; Duran I; Clarke BA; Oza AM
    Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors.
    Tao T; Shi H; Wang M; Perez-Atayde AR; London WB; Gutierrez A; Lemos B; Durbin AD; Look AT
    J Exp Med; 2020 Oct; 217(10):. PubMed ID: 32728700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.
    Giannini G; Di Marcotullio L; Ristori E; Zani M; Crescenzi M; Scarpa S; Piaggio G; Vacca A; Peverali FA; Diana F; Screpanti I; Frati L; Gulino A
    Cancer Res; 1999 May; 59(10):2484-92. PubMed ID: 10344762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.
    Kong XT; Choi SH; Inoue A; Xu F; Chen T; Takita J; Yokota J; Bessho F; Yanagisawa M; Hanada R; Yamamoto K; Hayashi Y
    Cancer Res; 1997 Sep; 57(17):3772-8. PubMed ID: 9288786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-1,4-Galactosyltransferase III enhances invasive phenotypes via β1-integrin and predicts poor prognosis in neuroblastoma.
    Chang HH; Chen CH; Chou CH; Liao YF; Huang MJ; Chen YH; Wang WJ; Huang J; Hung JS; Ho WL; Jeng YM; Che MI; Lee H; Lu MY; Yang YL; Jou ST; Lin DT; Lin KH; Hsu WM; Huang MC
    Clin Cancer Res; 2013 Apr; 19(7):1705-16. PubMed ID: 23444218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [mTOR inhibitor].
    Muro K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.